Key Takeaways
CVS Health's fiscal year 2025 (calendar year ended December 31, 2025) was a pivotal restructuring year — the company's most significant operational reset since the 2018 Aetna acquisition — as CVS divested non-core assets, appointed a new CEO (David Joyner, who replaced Karen Lynch in October 2024), and fundamentally repositioned the Health Care Benefits (insurance/Aetna) segment after the catastrophic margin collapse of FY2024. Total revenue reached approximately $383-392B, roughly flat to slightly down from FY2024's $372.8B, as prior-year Medicare Advantage reserve increases and pharmacy benefit management repricing headwinds moderated; however, the HCB segment Medical Benefit Ratio (MBR) — the percentage of premium revenue paid out in claims — remained elevated at approximately 90%+ versus the 85-87% long-term target, reflecting the persistent medical cost inflation from behavioral health, outpatient procedures, and GLP-1 drug utilization that triggered FY2024's earnings collapse. Adjusted EPS reached approximately $6.00-6.50, a partial recovery from FY2024's approximately $5.11 but still far below the $8.73 peak of FY2023, as HCB margin pressure was only partially offset by Pharmacy & Consumer Wellness and Health Services (PBM/MinuteClinic/Signify Health) segment stability. The FY2026 thesis is a binary Medicare Advantage normalization bet: if medical cost trends stabilize and CVS's pricing actions for FY2026 MA plans (submitted to CMS in early FY2025 with premium rate increases) are sufficient to restore HCB MBR toward 87-88%, EPS recovers toward $7.50-8.00 and the $9+ peak becomes a visible multi-year target. If MA utilization continues surprising to the upside, the stock's valuation remains impaired as investors discount the earnings quality.
CVS Health was founded in 1963 as Consumer Value Stores by Stanley Goldstein and colleagues in Lowell, Massachusetts, and grew into the largest pharmacy retailer in the United States through decades of acquisition and organic growth. The company's strategic transformation from pharmacy retailer to integrated health company began in earnest with the $78B acquisition of Aetna (one of the nation's largest health insurers) in 2018, followed by the $8B acquisition of Signify Health (in-home health assessments) in 2022 and the $10.6B acquisition of Oak Street Health (primary care clinics) in 2023. These acquisitions built the theoretical foundation of the "health hub" model: CVS retail pharmacies as the front door for health services, MinuteClinics for urgent care, Signify for in-home assessments, Oak Street for complex primary care, and Aetna insurance for risk and payment — a vertically integrated health system without the hospital. CEO David Joyner took over in October 2024 with a mandate from the board to stabilize the HCB segment and evaluate strategic alternatives for underperforming assets, including a potential separation of the insurance business from the pharmacy/health services business.
Business Structure
CVS reports four segments.
Health Care Benefits (HCB/Aetna) (~$127B revenue, ~33% of total): Medical insurance for Medicare Advantage (~4.4M members), Medicaid managed care, Commercial employer plans, and individual ACA marketplace plans. The HCB segment is the source of FY2024-FY2025 earnings distress: Medicare Advantage, which accounts for approximately 60% of HCB premiums, experienced unprecedented medical cost inflation from post-COVID behavioral health catch-up, higher outpatient procedure utilization, and GLP-1 obesity drug prescription costs that were not adequately priced into FY2024 MA premiums submitted to CMS in 2023.
Health Services (CVS Caremark/PBM + MinuteClinic + Signify + Oak Street) (~$175B revenue, ~45%): The pharmacy benefit management business (Caremark, one of the three largest US PBMs along with Express Scripts and OptumRx), MinuteClinic urgent care, Signify Health in-home assessment, and Oak Street primary care. PBM revenue is primarily pass-through (drug costs from manufacturers paid to pharmacies), so the revenue is large but the margin is thin; Caremark's value-add is formulary management, drug utilization review, and rebate negotiation.
Pharmacy & Consumer Wellness (~$88B revenue, ~23%): CVS retail pharmacy (~9,000 locations) and specialty pharmacy. The retail pharmacy segment is facing secular headwinds from Amazon Pharmacy, Mark Cuban's CostPlus Drugs, and PBM reimbursement rate reductions that compress front-end and dispensing margins.
Key Core Metrics Performance
Revenue and HCB Medical Benefit Ratio (FY2021–FY2025)
The HCB Medical Benefit Ratio (MBR) is the most important metric for CVS's earnings trajectory.
| Fiscal Year | Total Revenue | HCB Revenue | HCB MBR | Adj. EPS |
|---|---|---|---|---|
| FY2021 | $292.1B | ~$83B | 85.4% | $8.21 |
| FY2022 | $322.5B | ~$97B | 85.9% | $8.69 |
| FY2023 | $357.8B | ~$109B | 85.2% | $8.73 |
| FY2024 | $372.8B | ~$120B | 92.0%+ | ~$5.11 |
| FY2025 | ~$388B | ~$127B | ~90-91% | ~$6.25 |
The FY2024 MBR spike to 92%+ (versus the 85-87% target) destroyed approximately $3.5B in HCB operating income versus normalized expectations, producing the largest earnings miss in CVS's history and a 40%+ stock decline. FY2025 shows partial improvement as pricing actions took effect, but full MBR normalization to 87-88% requires another year of premium rate increases and utilization management tightening.
Adjusted EPS by Driver (FY2022–FY2025)
| Component | FY2022 | FY2023 | FY2024 | FY2025E |
|---|---|---|---|---|
| HCB operating income | ~$5.5B | ~$6.0B | ~$1.5B | ~$2.5B |
| Health Services op. income | ~$4.2B | ~$4.6B | ~$4.7B | ~$4.8B |
| Pharmacy & Consumer op. income | ~$3.0B | ~$2.8B | ~$2.5B | ~$2.3B |
| Total adjusted op. income | ~$13B | ~$13.4B | ~$8.4B | ~$9.5B |
| Adj. EPS | $8.69 | $8.73 | ~$5.11 | ~$6.25 |
Health Services operating income has been remarkably stable — Caremark PBM, MinuteClinic, and the newer primary care assets generate consistent cash flow. The entire earnings volatility is in HCB, making MA medical cost trend the single most important external driver for CVS's investment case.
Medicare Advantage Membership and Premium Rate Actions (FY2022–FY2025)
| Fiscal Year | MA Members | Premium Rate Change (CMS) | Member Growth |
|---|---|---|---|
| FY2022 | ~3.7M | +5.2% | +12% |
| FY2023 | ~4.1M | +8.5% | +11% |
| FY2024 | ~4.3M | +3.7% (underfunded) | +5% |
| FY2025 | ~4.4M | +5.1% (CMS funded) + CVS pricing actions | +2% |
The FY2024 CMS rate of +3.7% was materially insufficient to cover actual medical cost inflation of +7-9% in MA — the shortfall created the MBR disaster. FY2025-FY2026 pricing actions are designed to restore MBR toward 87-88%; if successful, the margin recovery thesis is intact.
Market Evaluation
CVS trades at approximately 8-12x forward adjusted EPS — a significant discount to the S&P 500 that reflects the market's skepticism about MA normalization timing and the structural questions about the integrated health model's competitiveness. The bull case is MBR normalization: if FY2026 MA premiums (filed with CMS in early FY2025 with ~10%+ rate increases) are sufficient to restore MBR to 87-88% and utilization does not surprise further to the upside, EPS recovers toward $7.50-8.00 — implying 40-60% upside from current depressed multiples. The pharmacy segment's secular headwinds (Amazon Pharmacy, CostPlus Drugs) are real but slower-moving than the MA crisis; the Oak Street primary care and Signify in-home assessment assets create a clinical capability that could differentiate CVS's MA product over 3-5 years. The bear case is structural MA disruption: if CMS continues tightening MA risk adjustment methodologies and prior authorization rules, and if GLP-1 utilization continues rising at 40%+ annually without adequate premium recovery, CVS faces a fundamentally unprofitable MA business that must be restructured or sold.
Medicare Advantage Cost Trajectory and the GLP-1 Wildcard
Medicare Advantage's medical cost inflation has two primary drivers in FY2024-FY2026 that CVS's actuaries initially underestimated. The first is post-COVID behavioral health catch-up: millions of MA beneficiaries deferred mental health treatment, addiction services, and elective medical procedures during 2020-2022 and are now accessing these services simultaneously, creating a utilization surge that is structural rather than temporary. The second is GLP-1 drug utilization: Ozempic, Wegovy, and Mounjaro have rapidly moved from Type 2 diabetes management (where they were expected) to obesity treatment (where MA beneficiaries are requesting coverage at rates that were not anticipated in FY2024 premium pricing). GLP-1 drugs cost approximately $12,000-15,000 per patient per year, and even 1% of CVS's 4.4M MA members using GLP-1 drugs for obesity adds approximately $500M+ in unanticipated pharmacy benefit costs.
CVS's response — negotiating manufacturer rebates on GLP-1 drugs through Caremark's PBM formulary, implementing prior authorization for obesity indication (versus diabetes), and filing significantly higher FY2026 MA premiums — represents the actuarial correction. The critical uncertainty is whether FY2026 utilization trends (filed and priced in early FY2025 based on incomplete FY2024 data) adequately capture the run-rate behavioral health and GLP-1 costs, or whether the actuarial correction is still running one year behind actual trends.